Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Accenture
Chubb
Chinese Patent Office
Boehringer Ingelheim
UBS
US Department of Justice
Julphar
Moodys
McKesson

Generated: February 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,770,675

« Back to Dashboard

Which drugs does patent 6,770,675 protect, and when does it expire?

Patent 6,770,675 protects RESCULA and is included in one NDA.
Summary for Patent: 6,770,675
Title: Compositions and methods for reducing ocular hypertension
Abstract:An improved ophthalmic composition, including docosanoid active agents, which is especially useful in lowering intraocular pressure associated with glaucoma. Improvements in IOP reduction efficacy, preservative efficacy and reduced additive concentrations are achieved by utilizing the disclosed compositions which include a docosanoid active agent (e.g., isopropyl unoprostone), in conjunction with selected non-ionic surfactants, preservatives, and non-ionic tonicity adjusting agents.
Inventor(s): Reed; Kenneth Warren (Lawrenceville, GA), Yen; Shau Fong (Atlanta, GA), Sou; Mary (Alpharetta, GA), Peacock; Regina Flinn (Alpharetta, GA)
Assignee: Novartis AG (Bern, CH)
Application Number:09/812,162
Patent Claim Types:
see list of patent claims
Composition; Use; Formulation;

Drugs Protected by US Patent 6,770,675

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sucampo Pharma Llc RESCULA unoprostone isopropyl SOLUTION/DROPS;OPHTHALMIC 021214-001 Aug 3, 2000 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y METHOD OF REDUCING OCULAR HYPERTENSION ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Covington
Mallinckrodt
AstraZeneca
Citi
Queensland Health
Federal Trade Commission
Accenture
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot